Advertisement

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Sep
16
Today In Oncology
Ivonescimab Significantly Improves Overall Survival vs Pembrolizumab in PD-L1–Positive Advanced NSCLC
Izalontamab Brenitecan Active in Previously Treated EGFR NSCLC
DAROL Examines Darolutamide With Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer
MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for SCLC
New Executive Director of the Duke Cancer Institute Named
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo